Lipid-Lowering Medication for Secondary Prevention of Coronary Heart Disease in a German Outpatient Population: The Gap Between Treatment Guidelines and Real Life Treatment Patterns
- 1 July 2002
- journal article
- clinical trial
- Published by Elsevier in Preventive Medicine
- Vol. 35 (1), 48-53
- https://doi.org/10.1006/pmed.2002.1050
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- The therapeutic gap — compliance with medication and guidelinesAtherosclerosis, 1999
- Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE Trial)The American Journal of Cardiology, 1999
- Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies* on Coronary PreventionJournal Of Hypertension, 1998
- EUROASPIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal resultsEuropean Heart Journal, 1997
- Clarifying the Direct Relation between Total Cholesterol Levels and Death from Coronary Heart Disease in Older PersonsAnnals of Internal Medicine, 1997
- Adherence to National Cholesterol Education Program Treatment Goals in Postmenopausal Women With Heart DiseasePublished by American Medical Association (AMA) ,1997
- Inadequate treatment with HMG-CoA reductase inhibitors by health care providersAmerican Journal Of Medicine, 1996
- Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goalsAmerican Journal Of Medicine, 1996
- Discontinuation of Antihyperlipidemic Drugs — Do Rates Reported in Clinical Trials Reflect Rates in Primary Care Settings?New England Journal of Medicine, 1995
- Recent Trends in the Identification and Treatment of High Blood Cholesterol by PhysiciansJAMA, 1993